Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

  • Technology appraisal guidance
  • TA687
  • Published: 

History

Expected publication

Final draft guidance

Committee meetings

Invitation to participate